首页> 外文OA文献 >Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.

【2h】

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.

机译：GC1008（fresolimumab）的I期研究：人类抗转化生长因子-β（TGFβ）单克隆抗体用于晚期恶性黑素瘤或肾细胞癌患者。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
John C Morris; Antoinette R Tan; Thomas E Olencki; Geoffrey I Shapiro; Bruce J Dezube; Michael Reiss; Frank J Hsu; Jay A Berzofsky; Donald P Lawrence;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. [J] . Rudman SM, Jameson MB, McKeage MJ, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第7期

机译：AS1409是一种新型抗体-细胞因子融合蛋白，用于恶性黑色素瘤或肾细胞癌患者的1期研究。
2. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). [J] . Kollmannsberger C, Schittenhelm M, Honecker F, Annals of oncology: official journal of the European Society for Medical Oncology . 2006,第6期

机译：人源化单克隆抗表皮生长因子受体（EGFR）抗体EMD 72000（matuzumab）与紫杉醇联合用于EGFR阳性晚期非小细胞肺癌（NSCLC）患者的I期研究。
3. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC) [J] . C. Kollmannsberger, M. Schittenhelm, F. Honecker, Annals of Oncology . 2006,第6期

机译：人源化单克隆抗表皮生长因子受体（EGFR）抗体EMD 72000（matuzumab）与紫杉醇联合用于EGFR阳性晚期非小细胞肺癌（NSCLC）患者的I期研究
4. Characterization of cancer specific human monoclonal IgM antibodies produced by hybridomas derived from a patient with adult T-cell leukemia [C] . T. KAWAHARA, A. ICHIKAWA, Y. KATAKURA, Annual Meeting of the Japanese Association for Animal Cell Technology . 2002

机译：杂交瘤产生的癌症特异性人单克隆IgM抗体的表征衍生自成人T细胞白血病患者的杂交瘤
5. Cloning and expression of a biosimilar chimeric monoclonal antibody directed against the human epidermal growth factor receptor and its production in CHO cells for treatment of colo-rectal cancer. [D] . Motiwala, Hatim Maqbulhusen. 2012

机译：针对人表皮生长因子受体的生物仿制药嵌合单克隆抗体的克隆和表达及其在CHO细胞中的产生，用于治疗结肠直肠癌。
6. Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma [O] . John C. Morris, Antoinette R. Tan, Thomas E. Olencki, -1

机译：GC1008（Fresolimumab）的I期研究：晚期恶性黑色素瘤或肾细胞癌患者的人抗转化生长因子-β（TGFβ）单克隆抗体
7. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008) [O] . Mario E. Lacouture, John C. Morris, Donald P. Lawrence, 2015

机译：与单克隆抗体FRESOLIMABAB（GC1008）中和转化生长因子β相关的皮肤角膜饼瘤/鳞状细胞癌

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.

著录项

引文网络

相似文献

相关主题

期刊订阅